[Clinical benefit of Tocilizumab and other immunomodulating agents for treatment of COVID-19]. / Klinischer Nutzen von Tocilizumab und anderen immunmodulatorischen Substanzen bei COVID-19.
Dtsch Med Wochenschr
; 146(23): 1538-1542, 2021 Nov.
Article
in German
| MEDLINE | ID: covidwho-1537357
ABSTRACT
The pathophysiological course of COVID-19 can be distinguished in a phase of viral replication and an inflammatory phase. Hyperinflammatory processes promote the development of severe COVID-19. Therefore, immunomodulating agents came into focus. Dexamethasone has already become standard of care for treatment of severe COVID-19. Two large randomized trials and a meta-analysis of collectively nine randomized trials showed a reduced mortality in patients with severe COVID-19 if Tocilizumab - an IL-6-rezeptor antagonist - was added to standard of care. Treatment with Baricitinib - a JAK 1/2 inhibitor - may also be beneficial for patients without or on low oxygen supplementation. National and international guidelines recommend Tocilizumab for treatment of severe COVID-19. Treatment with JAK inhibitors is an option for hospitalized patients with moderate COVID-19. It should be emphasized that comedication of JAK inhibitors and Tocilizumab is not recommended. Further high quality research is required for the widespread use of immunomodulating agents in COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Monoclonal, Humanized
/
Immunomodulating Agents
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
German
Journal:
Dtsch Med Wochenschr
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS